Sugi Predict

Sugi Predict / Compounds / SCHEMBL15224428

SCHEMBL15224428

SCHEMBL15224428

CSc1nc(Cl)n2ncc(C(C)C)c2n1

nearest known ligand 0.34

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 3/20 0.34
▸ CDK5 Q00535 3/20 0.34
▸ CDK5R1 Q15078 3/20 0.34
▸ SRC P12931 6/20 0.31
▸ ABL1 P00519 3/20 0.31
▸ HCK P08631 2/20 0.31
▸ PIM1 P11309 2/20 0.31
▸ CDK9 P50750 2/20 0.31
▸ CCNT1 O60563 1/20 0.30
▸ CCNA2 P20248 1/20 0.30
▸ CCNE1 P24864 1/20 0.30
▸ CDK7 P50613 1/20 0.30
▸ CCNH P51946 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29842129 0.84 SRC (0.35) CDK2CDK5CDK5R1SRCABL1
SCHEMBL15238066 0.81 CDK2 (0.32) CDK2CDK5CDK5R1SRCHCK
SCHEMBL23508176 0.81 SRC (0.30) SRCABL1HCKPIM1
SCHEMBL21855481 0.80 CDK2 (0.36) CDK2CDK5CDK5R1CDK9CCNT1
SCHEMBL16659551 0.79 CDK2 (0.36) CDK2CDK5CDK5R1SRCHCK
SCHEMBL11916288 0.79 KDM4E (0.36) SRCABL1HCKPIM1
SCHEMBL23713346 0.79 CDK2 (0.36) CDK2CDK5CDK5R1CDK9CCNT1
SCHEMBL6892897 0.78 GSK3B (0.37) CDK2SRCABL1HCKPIM1
SCHEMBL26696795 0.76 RAB9A (0.37) CDK2CDK5CDK5R1SRCHCK
SCHEMBL23381889 0.75 POLB (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119139317-B Application of compound in preparation of medicines for treating allergic rhinitis 中国科学院杭州医学研究所 2025-03-28 — — CN claimed
CN-119139317-A Application of compound in preparation of medicines for treating allergic rhinitis 中国科学院杭州医学研究所 2024-12-17 — — CN claimed
CN-119139317-B Application of compound in preparation of medicines for treating allergic rhinitis 中国科学院杭州医学研究所 2025-03-28 — — CN disclosed
CN-119139317-A Application of compound in preparation of medicines for treating allergic rhinitis 中国科学院杭州医学研究所 2024-12-17 — — CN disclosed
WO-2024175024-A1 NEW FUSED HETEROCYCLIC COMPOUND AS CDKS INHIBITOR AND USE THEREOF 杭州德睿智药科技有限公司 2024-08-29 — — WO disclosed
WO-2024125532-A1 NOVEL HETEROCYCLIC COMPOUND ACTING AS CDKS INHIBITOR, AND USE THEREOF 杭州德睿智药科技有限公司 2024-06-20 — — WO disclosed
US-20240166693-A1 METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 Design Therapeutics, Inc. 2024-05-23 — — US disclosed
CN-117843642-A Difunctional compound and application thereof 麦科萨药业(苏州)有限公司 2024-04-09 — — CN disclosed
US-11858937-B2 Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors QURIENT CO., LTD. (KR) 2024-01-02 — — US disclosed
US-11858937-B2 Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors QURIENT CO., LTD. (KR) 2024-01-02 — — US disclosed
WO-2023227125-A1 NEW FUSED-HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF 杭州德睿智药科技有限公司 2023-11-30 — — WO disclosed
US-20150111873-A1 PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES LEAD DISCOVERY CENTER GMBH (DE) 2015-04-23 — — US disclosed
US-20150111873-A1 PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES LEAD DISCOVERY CENTER GMBH (DE) 2015-04-23 — — US disclosed
US-20150111873-A1 PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES LEAD DISCOVERY CENTER GMBH (DE) 2015-04-23 — — US disclosed
WO-2013128028-A1 PYRAZOLO - TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN- DEPENDENT KINASE INHINITORS LEAD DISCOVERY CENTER GMBH (DE) 2013-09-06 — — WO disclosed
WO-2013128029-A1 PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES LEAD DISCOVERY CENTER GMBH (DE) 2013-09-06 — — WO disclosed
EP-2634190-A1 Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors Lead Discovery Center GmbH (DE) 2013-09-04 — — EP disclosed
EP-2634189-A1 Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors Lead Discovery Center GmbH (DE) 2013-09-04 — — EP disclosed
EP-2634189-A1 Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors Lead Discovery Center GmbH (DE) 2013-09-04 — — EP disclosed
EP-2634190-A1 Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors Lead Discovery Center GmbH (DE) 2013-09-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858937-B2 Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors CDKL5, CDK15, CDK5 CDK2 9/4885CDK5 3/4885CDK5R1 13/4885
US-20240166693-A1 METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 MTPN, DMPK, MBNL1 CDK2 801/4885CDK5 271/4885CDK5R1 200/4885
US-20150111873-A1 PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES PAK5, STK35, TESK2 CDK2 468/4885CDK5 67/4885CDK5R1 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.